New drugs to treat tuberculosis

F1000 Medicine Reports

Volumn 4, Issue 1, 2012, Pages

  Swindells, Susan ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOSALICYLIC ACID; AZD 5847; BCG VACCINE; BEDAQUILINE; CLOFAZIMINE; CYCLOSERINE; DACTINOMYCIN; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RIFATER; STREPTOMYCIN; STREPTOTHRICIN; SUTEZOLID; TCM 207; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERICIDAL ACTIVITY; BCG VACCINATION; CAUSE OF DEATH; DRUG MEGADOSE; EPIDEMIC; EXPERIMENTAL MODEL; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LUNG TUBERCULOSIS; NONHUMAN; REVIEW; SPUTUM CULTURE; THROMBOCYTOPENIA; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 84862208520     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M4-12     Document Type: Review

References (44)

1. Global Tuberculosis Control 2011 [http://www.who.int/tb/publications/ global-report/en/index.html]
2. The World Health Report 2004 [http://www.who.int/whr/2004/annex/topic/en/ annex-2-en.pdf]
3. 2009 Tuberculosis and Women [http://www.who.int/tb/challenges/gender/ factsheet-womenandtb.pdf]
4. HIV and TB [http://www.cdc.gov/hiv/resources/factsheets/PDF/hivtb.pdf]
5. Young DB, Perkins MD, Duncan K, Barry CE: Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 2008, 118:1255-65. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
6. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M: Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007, 5:857-71. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
7. Swaminathan S, Rekha B: Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010, 50(Suppl 3):S184-94.
8. Rapid Advice: Treatment of Tuberculosis in Children [http://whqlibdoc. who.int/publications/2010/9789241500449-eng.pdf]
9. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V: Pharmacokinetics- pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003, 47:2118-24. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
10. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL: Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007, 4:e344. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
11. Burman WJ: Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis 2010, 50(Suppl 3):S165-72. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
12. Critical Path to TB Drug Regimens (CPTR) [http://www.c-path.org/CPTR.cfm]
13. Diacon A, Dawson R, Van Niekerk C, Eroundu N, Ginsberg A: Pyrazinamide increases the early bactericidal activity of TMC207 and PA-824 in patients with newly diagnosed, smear-positive pulmonary tuberculosis [abstract]. Presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy: 17-20 September, 2011; Chicago, IL.
14. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PPJ, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W: CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med 2011, 184:972-9.
15. Peloquin C: What is the 'right' dose of rifampin? Int J Tuberc Lung Dis 2003, 7:3-5. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
16. Martínez E, Collazos J, Mayo J: Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 1999, 78:361-9. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
17. Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C: Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis 2012, 16:6-15. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
18. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Chaisson RE: Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011, 365:2155-66. Changes Clinical Practice F1000 Factor 13 Evaluated by David Griffith 22 Dec 2011, Richard ZuWallack and Fatima Ajaz 10 Jan 2012, Anthony Harries 10 Feb 2012, Susan Swindells 17 May 2012
19. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011, 60:1650-3. Changes Clinical Practice F1000 Factor 11 Evaluated by David Griffith 22 Dec 2011, Susan Swindells 17 May 2012
20. Dorman S, Goldberg S, Feng P, Heilig C, Stout JE, Schluger NW, Moro R, Bozeman L, Johnson JL, Muzanye G, Nahid P, Narita M, Ray S, Bates E, Haile B, Weiner M, Vernon AA: A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: Preliminary results for Tuberculosis Trials Consortium Study 29. Am J Respir Crit Care Med 2011, 183:A6413. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
21. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, Alston-Smith B, Acosta EP: Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009, 50:290-3. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
22. Dooley K: CYP3A induction by rifampin and rifapentine: Which drug and dose does it best? [abstract] Presented at 4th Int Wkshp Clin Pharmacol of TB Drugs September 2011; Chicago, IL.
23. Rodríguez JC, Ruiz M, López M, Royo G: In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002, 20:464-7. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
24. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA: A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-38. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
25. Conde MB, Efron A, Loredo C, de Souza GRM, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE: Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-9. F1000 Factor 6 Evaluated by Ric Price and Krispin Hajkowicz 05 May 2009
26. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE: Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 174:331-8. (Pubitemid 44156613)
27. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE: Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-80. F1000 Factor 8 Evaluated by Terence Seemungal and Saeeda Mohammed 17 Aug 2009
28. van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:684-92. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
29. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J, Winkler H, van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-7. F1000 Factor 19 Evaluated by Matthias Maiwald 22 Dec 2004, Ken Wilson 27 Jan 2005, Wolfgang Junge 01 Feb 2005, Thomas Meier 20 Oct 2009, Susan Swindells 17 May 2012
30. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, de Marez T, van Heeswijk RPG, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-405. F1000 Factor 8 Evaluated by Anthony Harries 17 Jun 2009, Susan Swindells 17 May 2012
31. McNeeley DF, the TMC207 Team, Diacon AH, Pym A, Grobusch MP, Gotuzzo E, Ticona E, De los Rios J, Le Maine V: TMC-207 versus placebo plus OBT for the treatment of MDR-TB: a prospective clinical trial. [abstract] Presented at Proceedings of the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union): 11-15 November 2010; Berlin, Germany.
32. Dooley KE, Park J, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C: Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr 2012, 59:455-62.
33. Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, Scherman MS, Cho SH, McNeil MR, Lenaerts AJ, Franzblau SG, Meibohm B, Lee RE: A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 2008, 62:1037-45. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
34. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M: OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006, 3:e466.
35. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E: Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2008, 52:3664-8. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
36. Diacon A, Dawson R, Van Niekerk C, Erondu N, Ginsberg A: Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB. [abstract] Presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy: 17-20 September 2011; Chicago, IL.
37. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA: Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007, 51:1563-5. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
38. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA: Synergistic interactions of SQ109, a new ethylene diamine, with frontline antitubercular drugs in vitro. J Antimicrob Chemother 2006, 58:332-7. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
39. Cynamon MH, Klemens SP, Sharpe CA, Chase S: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43:1189-91. (Pubitemid 29214745)
40. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, de García Viedma D, Díaz-Infantes M, Marín-Arriaza M, Bouza E: In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to firstline antituberculous drugs. Antimicrob Agents Chemother 2003, 47:416-7. (Pubitemid 36070399)
41. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S: Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010, 50:49-55. F1000 Factor 8 Evaluated by Roman Kozlov and Sergey Yakushin 09 Mar 2010
42. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger J, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C: A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009, 34:387-93.
43. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E: Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009, 53:1314-9. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012
44. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL: Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009, 180:371-6. F1000 Factor 6 Evaluated by Susan Swindells 17 May 2012